David Liebowitz

Biography

Dr. David Liebowitz has preclinical and clinical development experience in Oncology, Infectious Diseases (Virology), Inflammation and Metabolic Disorders using protein, small molecule and vaccine therapeutic modalities. In addition to his work with BioPharma Consulting Services, Dr. Liebowitz is also the Chief Scientific and Medical Officer for Vivaldi Biosciences, an influenza vaccine and therapeutics biotechnology company. Prior to that, he was Executive Vice President and Chief Scientific Officer at Galileo Pharmaceuticals, a small molecule drug discovery and development company, focused on Inflammation and Metabolic Disorders. He also served as co-CEO of Galileo for a short period of time. Prior to joining Galileo, Dr. Liebowitz was at Amgen, where he served as the Director of Research responsible for all Oncology drug discovery and development programs at the Amgen Washington research site. He also managed external development collaborations and licensing activities. Dr. Liebowitz joined Amgen through their acquisition of Immunex. He was recruited to Immunex as a Medical Director (Oncology) in Clinical Development. Later he moved within the Immunex organization to start a new research therapeutic area in Oncology. Prior to joining Immunex, he was an Associate Investigator in the Abramson Cancer Institute at the University of Pennsylvania, where he served as Director of their Immunotherapy and Cellular Therapy Programs targeting cancer and chronic viral diseases. Dr. Liebowitz was an early recipient of a grant from the Bill and Melinda Gates foundation. He began his academic career as an Assistant Professor of Medicine and Virology at the University of Chicago, and was the Director of the Bone Marrow Transplantation Program. Dr. Liebowitz has B.S. and M.S. degrees in Biology from Emory University, an M.D. with Honors and a Ph.D. in Molecular Genetics and Cell Biology, both from the University of Chicago.

Research Interest

Molecular Genetics and Cell Biology